AAAAAA

   
Results: 1-25 | 26-33
Results: 1-25/33
OPENING COMMENTS - 20TH ANNIVERSARY OF INSTITUT-FUR-KLINISCHE-PHARMAKOLOGIE-BOBENHEIM PROF. DR. LUCKER GMBH, APRIL 11, 1997
Authors: LUCKER PW
Citation: Pw. Lucker, OPENING COMMENTS - 20TH ANNIVERSARY OF INSTITUT-FUR-KLINISCHE-PHARMAKOLOGIE-BOBENHEIM PROF. DR. LUCKER GMBH, APRIL 11, 1997, Methods and findings in experimental and clinical pharmacology, 20(6), 1998, pp. 501-503
URINARY-EXCRETION OF ACETAZOLAMIDE IN HEALTHY-VOLUNTEERS AFTER SHORT-TERM AND LONG-TERM EXPOSURE TO HIGH-ALTITUDE
Authors: RITSCHEL WA PAULOS C ARANCIBIA A AGRAWAL MA WETZELSBERGER KM LUCKER PW
Citation: Wa. Ritschel et al., URINARY-EXCRETION OF ACETAZOLAMIDE IN HEALTHY-VOLUNTEERS AFTER SHORT-TERM AND LONG-TERM EXPOSURE TO HIGH-ALTITUDE, Methods and findings in experimental and clinical pharmacology, 20(2), 1998, pp. 133-137
EFFECT OF DIFFERENTLY PROCESSED COFFEE ON THE GASTRIC POTENTIAL DIFFERENCE AND INTRAGASTRIC PH IN HEALTHY-VOLUNTEERS
Authors: EHRLICH A BASSE H HENKELERNST J HEY B MENTHE J LUCKER PW
Citation: A. Ehrlich et al., EFFECT OF DIFFERENTLY PROCESSED COFFEE ON THE GASTRIC POTENTIAL DIFFERENCE AND INTRAGASTRIC PH IN HEALTHY-VOLUNTEERS, Methods and findings in experimental and clinical pharmacology, 20(2), 1998, pp. 155-161
EQUIPOTENT INHIBITION OF GASTRIC-ACID SECRETION BY EQUAL DOSES OF ORAL OR INTRAVENOUS PANTOPRAZOLE
Authors: HARTMANN M EHRLICH A FUDER H LUHMANN R EMEKLIBAS S TIMMER W WURST W LUCKER PW
Citation: M. Hartmann et al., EQUIPOTENT INHIBITION OF GASTRIC-ACID SECRETION BY EQUAL DOSES OF ORAL OR INTRAVENOUS PANTOPRAZOLE, Alimentary pharmacology & therapeutics, 12(10), 1998, pp. 1027-1032
PHARMACOKINETICS OF ACETAZOLAMIDE IN HEALTHY-VOLUNTEERS AFTER SHORT-TERM AND LONG-TERM EXPOSURE TO HIGH-ALTITUDE
Authors: RITSCHEL WA PAULOS C ARANCIBIA A AGRAWAL MA WETZELSBERGER KM LUCKER PW
Citation: Wa. Ritschel et al., PHARMACOKINETICS OF ACETAZOLAMIDE IN HEALTHY-VOLUNTEERS AFTER SHORT-TERM AND LONG-TERM EXPOSURE TO HIGH-ALTITUDE, Journal of clinical pharmacology, 38(6), 1998, pp. 533-539
INFLUENCE OF CHOLESTYRAMINE ON THE PHARMACOKINETICS OF CERIVASTATIN
Authors: MUCK W RITTER W FREY R WETZELSBERGER N LUCKER PW KUHLMANN J
Citation: W. Muck et al., INFLUENCE OF CHOLESTYRAMINE ON THE PHARMACOKINETICS OF CERIVASTATIN, International journal of clinical pharmacology and therapeutics, 35(6), 1997, pp. 250-254
EFFECT OF BUFFERING ON PHARMACOKINETICS OF KETOPROFEN ENANTIOMERS IN MAN
Authors: FUDER H STIEGLER S WETZELSBERGER N WIECKHORST G LANGE R LUCKER PW
Citation: H. Fuder et al., EFFECT OF BUFFERING ON PHARMACOKINETICS OF KETOPROFEN ENANTIOMERS IN MAN, British journal of clinical pharmacology, 44(6), 1997, pp. 527-530
OPTIMIZING THE ABSORPTION OF VALSPODAR, A P-GLYCOPROTEIN MODULATOR .1. SELECTING AN ORAL FORMULATION AND EXPLORING ITS CLINICAL PHARMACOKINETICS DYNAMICS/
Authors: MUELLER EA KOVARIK JM URESIN Y PREISIGFLUCKIGER SS HENSEL S LUCKER PW HOLT B
Citation: Ea. Mueller et al., OPTIMIZING THE ABSORPTION OF VALSPODAR, A P-GLYCOPROTEIN MODULATOR .1. SELECTING AN ORAL FORMULATION AND EXPLORING ITS CLINICAL PHARMACOKINETICS DYNAMICS/, Journal of clinical pharmacology, 37(11), 1997, pp. 1001-1008
CONCOMITANT ADMINISTRATION OF THE ALPHA-GLUCOSIDASE INHIBITOR VOGLIBOSE (AO-128) DOES NOT ALTER THE PHARMACOKINETICS OF GLIBENCLAMIDE
Authors: KLEIST P EHRLICH A SUZUKI Y TIMMER W WETZELSBERGER N LUCKER PW FUDER H
Citation: P. Kleist et al., CONCOMITANT ADMINISTRATION OF THE ALPHA-GLUCOSIDASE INHIBITOR VOGLIBOSE (AO-128) DOES NOT ALTER THE PHARMACOKINETICS OF GLIBENCLAMIDE, European Journal of Clinical Pharmacology, 53(2), 1997, pp. 149-152
THE ALPHA-GLUCOSIDASE INHIBITOR VOGLIBOSE (AO-128) DOES NOT CHANGE PHARMACODYNAMICS OR PHARMACOKINETICS OF WARFARIN
Authors: FUDER H KLEIST P BIRKEL M EHRLICH A EMEKLIBAS S MASLAK W STRIDDE E WETZELSBERGER N WIECKHORST G LUCKER PW
Citation: H. Fuder et al., THE ALPHA-GLUCOSIDASE INHIBITOR VOGLIBOSE (AO-128) DOES NOT CHANGE PHARMACODYNAMICS OR PHARMACOKINETICS OF WARFARIN, European Journal of Clinical Pharmacology, 53(2), 1997, pp. 153-157
INFLUENCE OF CHOLESTYRAMINE ON THE PHARMACOKINETICS OF CERIVASTATIN
Authors: RITTER W FREYL R WETZELSBERGER N LUCKER PW
Citation: W. Ritter et al., INFLUENCE OF CHOLESTYRAMINE ON THE PHARMACOKINETICS OF CERIVASTATIN, Atherosclerosis, 130, 1997, pp. 123-123
PANTOPRAZOLE ONCE-DAILY VERSUS TWICE-DAILY - A PH-METRY STUDY
Authors: FUDER H EHRLICH A WIECKHORST G LUCKER PW CAIN CR
Citation: H. Fuder et al., PANTOPRAZOLE ONCE-DAILY VERSUS TWICE-DAILY - A PH-METRY STUDY, Gastroenterology, 112(4), 1997, pp. 120-120
EFFECT OF BUFFERING ON PHARMACOKINETICS OF KETOPROFEN (KN) ENANTIOMERS IN MAN
Authors: LANGE R FUDER H BIRKEL M WETZELSBERGER N LUCKER PW
Citation: R. Lange et al., EFFECT OF BUFFERING ON PHARMACOKINETICS OF KETOPROFEN (KN) ENANTIOMERS IN MAN, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 26-26
URINARY-EXCRETION OF MEPERIDINE AND NORMEPERIDINE IN MAN UPON ACUTE AND CHRONIC EXPOSURE TO HIGH-ALTITUDE
Authors: RITSCHEL WA PAULOS C ARANCIBIA A PEZZANI M AGRAWAL M WETZELSBERGER K LUCKER PW
Citation: Wa. Ritschel et al., URINARY-EXCRETION OF MEPERIDINE AND NORMEPERIDINE IN MAN UPON ACUTE AND CHRONIC EXPOSURE TO HIGH-ALTITUDE, Methods and findings in experimental and clinical pharmacology, 18(1), 1996, pp. 49-53
24-HOUR INTRAGASTRIC PH PROFILES AND PHARMACOKINETICS FOLLOWING SINGLE AND REPEATED ORAL-ADMINISTRATION OF THE PROTON PUMP INHIBITOR PANTOPRAZOLE IN COMPARISON TO OMEPRAZOLE
Authors: HARTMANN M THEISS U HUBER R LUHMANN R BLIESATH H WURST W LUCKER PW
Citation: M. Hartmann et al., 24-HOUR INTRAGASTRIC PH PROFILES AND PHARMACOKINETICS FOLLOWING SINGLE AND REPEATED ORAL-ADMINISTRATION OF THE PROTON PUMP INHIBITOR PANTOPRAZOLE IN COMPARISON TO OMEPRAZOLE, Alimentary pharmacology & therapeutics, 10(3), 1996, pp. 359-366
PHARMACOKINETICS OF MEPERIDINE IN HEALTHY-VOLUNTEERS AFTER SHORT-TERMAND LONG-TERM EXPOSURE TO HIGH-ALTITUDE
Authors: RITSCHEL WA PAULOS C ARANCIBIA A PEZZANI M AGRAWAL MA WETZELSBERGER KM LUCKER PW
Citation: Wa. Ritschel et al., PHARMACOKINETICS OF MEPERIDINE IN HEALTHY-VOLUNTEERS AFTER SHORT-TERMAND LONG-TERM EXPOSURE TO HIGH-ALTITUDE, Journal of clinical pharmacology, 36(7), 1996, pp. 610-616
LACK OF PHARMACODYNAMIC AND PHARMACOKINETIC INTERACTION BETWEEN PANTOPRAZOLE AND PHENPROCOUMON IN MAN
Authors: EHRLICH A FUDER H HARTMANN M WIECKHORST G TIMMER W HUBER R BIRKEL M BLIESATH H STEINIJANS VW WURST W LUCKER PW
Citation: A. Ehrlich et al., LACK OF PHARMACODYNAMIC AND PHARMACOKINETIC INTERACTION BETWEEN PANTOPRAZOLE AND PHENPROCOUMON IN MAN, European Journal of Clinical Pharmacology, 51(3-4), 1996, pp. 277-281
NO PHARMACOKINETIC INTERACTION BETWEEN THE ALPHA-GLUCOSIDASE INHIBITOR VOGLIBOSE (AO-128) AND GLIBENCLAMIDE IN HEALTHY-SUBJECTS
Authors: FUDER H KLEIST P EHRLICH A TIMMER W SUZUKI Y BIRKEL M WETZELSBERGER N LUCKER PW
Citation: H. Fuder et al., NO PHARMACOKINETIC INTERACTION BETWEEN THE ALPHA-GLUCOSIDASE INHIBITOR VOGLIBOSE (AO-128) AND GLIBENCLAMIDE IN HEALTHY-SUBJECTS, Naunyn-Schmiedeberg's archives of pharmacology, 354(4), 1996, pp. 123-123
MEPERIDINE UPTAKE AND BINDING TO HUMAN BLOOD EX-VIVO
Authors: RITSCHEL WA SHAPIROJACOBSON M AKILESWARAN R WETZELSBERGER K LUCKER PW
Citation: Wa. Ritschel et al., MEPERIDINE UPTAKE AND BINDING TO HUMAN BLOOD EX-VIVO, Methods and findings in experimental and clinical pharmacology, 17(7), 1995, pp. 477-481
EFFECT OF 4 LANSOPRAZOLE DOSE LEVELS AND ONE DOSAGE REGIMEN OF OMEPRAZOLE ON 24-HOUR INTRAGASTRIC PH IN HEALTHY-SUBJECTS
Authors: TIMMER W RIPKE H KLEIST P EHRLICH A WIECKHORST G LUCKER PW FUDER H
Citation: W. Timmer et al., EFFECT OF 4 LANSOPRAZOLE DOSE LEVELS AND ONE DOSAGE REGIMEN OF OMEPRAZOLE ON 24-HOUR INTRAGASTRIC PH IN HEALTHY-SUBJECTS, Methods and findings in experimental and clinical pharmacology, 17(7), 1995, pp. 489-495
A PILOT-STUDY ON THE DETERMINATION OF THE RELATIVE BIOAVAILABILITY OFLEVO-THYROXINE
Authors: TRANTOW T HERZOG R FUDER H ISE J LUCKER PW
Citation: T. Trantow et al., A PILOT-STUDY ON THE DETERMINATION OF THE RELATIVE BIOAVAILABILITY OFLEVO-THYROXINE, Methods and findings in experimental and clinical pharmacology, 17(5), 1995, pp. 333-343
RELATIVE BIOAVAILABILITY OF DL-OXYFEDRINE-ASTERISK-HCL AFTER SINGLE-DOSE ORAL-ADMINISTRATION OF TABLETS AS COMPARED TO EQUIMOLAR SOLUTIONS
Authors: WETZELSBERGER N BIRKEL M FUDER H LUCKER PW STIEGLER S SCHEITHAUER S THUMMLER D
Citation: N. Wetzelsberger et al., RELATIVE BIOAVAILABILITY OF DL-OXYFEDRINE-ASTERISK-HCL AFTER SINGLE-DOSE ORAL-ADMINISTRATION OF TABLETS AS COMPARED TO EQUIMOLAR SOLUTIONS, Methods and findings in experimental and clinical pharmacology, 17(3), 1995, pp. 185-191
PHARMACOKINETICS AND RELATIVE BIOAVAILABILITY AFTER SINGLE-DOSE ADMINISTRATION OF 25 MG KETOPROFEN SOLUTION AS COMPARED TO TABLETS
Authors: STIEGLER S BIRKEL M JOST V LANGE R LUCKER PW WETZELSBERGER N
Citation: S. Stiegler et al., PHARMACOKINETICS AND RELATIVE BIOAVAILABILITY AFTER SINGLE-DOSE ADMINISTRATION OF 25 MG KETOPROFEN SOLUTION AS COMPARED TO TABLETS, Methods and findings in experimental and clinical pharmacology, 17(2), 1995, pp. 129-134
LACK OF PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTION OF PANTOPRAZOLE AND PHENPROCOUMON IN MAN
Authors: EHRLICH A FUDER H HARTMANN M TIMMER W HUBER R BIRKEL M BLIESATH H STEINJIANS VW WURST W LUCKER PW
Citation: A. Ehrlich et al., LACK OF PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTION OF PANTOPRAZOLE AND PHENPROCOUMON IN MAN, Gastroenterology, 108(4), 1995, pp. 86-86
1ST ADMINISTRATION TO MAN OF THE NEW REVERSIBLE PROTON PUMP INHIBITOR-BY841 - TOLERABILITY, SAFETY AND PH-METRY
Authors: FUDER H HARTMANN M TIMMER W LUHMANN R WIECKHORST G HUBER R BLIESATH H WURST W POSTIUS S RADTKE HW LUCKER PW
Citation: H. Fuder et al., 1ST ADMINISTRATION TO MAN OF THE NEW REVERSIBLE PROTON PUMP INHIBITOR-BY841 - TOLERABILITY, SAFETY AND PH-METRY, Gastroenterology, 108(4), 1995, pp. 96-96
Risultati: 1-25 | 26-33